APA (7th ed.) Citation

Papp, K., Bachelez, H., Costanzo, A., Foley, P., Gooderham, M., Kaur, P., . . . Strober, B. (2017). Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal of the American Academy of Dermatology, 76(6), 1093-1102. https://doi.org/10.1016/j.jaad.2016.12.014

Chicago Style (17th ed.) Citation

Papp, Kim, et al. "Clinical Similarity of Biosimilar ABP 501 to Adalimumab in the Treatment of Patients with Moderate to Severe Plaque Psoriasis: A Randomized, Double-blind, Multicenter, Phase III Study." Journal of the American Academy of Dermatology 76, no. 6 (2017): 1093-1102. https://doi.org/10.1016/j.jaad.2016.12.014.

MLA (9th ed.) Citation

Papp, Kim, et al. "Clinical Similarity of Biosimilar ABP 501 to Adalimumab in the Treatment of Patients with Moderate to Severe Plaque Psoriasis: A Randomized, Double-blind, Multicenter, Phase III Study." Journal of the American Academy of Dermatology, vol. 76, no. 6, 2017, pp. 1093-1102, https://doi.org/10.1016/j.jaad.2016.12.014.